ecamsule (Mexoryl SX) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Also called Ecamsule (technical name terephthalylidine dicamphor sulfonic acid), Mexoryl SX is a synthetic sunscreen agent developed and patented by L’Oreal and used in the company’s sunscreen products sold outside the United States since 1993 (approved for use in Europe in 1991). Ecamsule affords broad spectrum protection against the sun’s UVB and UVA rays. Exposed to UV, ecamsule undergoes reversible photoisomerization, followed by photoexcitation. The absorbed UV is then released as thermal energy, without penetrating the skin. The UVB range is 280 to 320 nanometers, and the UVA range is 320 to 400. Ecamsule protects against UV wavelengths in the 290–400 nanometer range, with peak protection at 345 nm.[3][4] Since ecamsule doesn't cover the entire UV spectrum, it should be combined with other active sunscreen agents to ensure broad-spectrum UV protection. Ecamsule is a photostable organic UVA absorber, meaning it doesn't degrade significantly when exposed to light.   NCATS

Chemistry

  • SMILES: CC1(C)C2CCC1(CS(=O)(=O)O)C(=O)C2=Cc1ccc(C=C2C(=O)C3(CS(=O)(=O)O)CCC2C3(C)C)cc1
  • InChIKey: HEAHZSUCFKFERC-UHFFFAOYSA-N
  • Mol. Mass: 562.71
  • ALogP: 4.24
  • ChEMBL Molecules:
    ecamsule  
    None  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Topical
  • Pro Drug: No

Combination drugs

( titanium, octocrylene, avobenzone (shade uvaguard), ecamsule (Mexoryl SX) )
|
( octocrylene, avobenzone (shade uvaguard), ecamsule (Mexoryl SX) - other name: capital soleil )

Alternative names

3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfonic acid) | ((3z)-3-((4-((z)-(7,7-dimethyl-3-oxo-4-(sulfomethyl)norbornan-2-ylidene)methyl)phenyl)methylidene)-7,7-dimethyl-2-oxo-norbornan-1-yl)methanesulfonic acid | ecamsule | mexoryl | mexoryl sx | terephthalylidene dicamphor sulfonic acid

Organizations (5)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (2)


 

Skin Diseases (approved 1991)

Sunburn (approved 2006)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Dermatology (Phase 2/Phase 3)

Melanosis (Phase 4)

Nerve Sheath Neoplasms (Phase 2)

Photosensitivity Disorders ()

Sunburn (Phase 3)

Tumor Suppressor Protein p53 (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue